EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis

Nico Gagelmann iD, Gabriela S Hobbs, Edoardo Campodonico, Grzegorz Helbig, Polona Novak, Thomas Schroeder, Artur Schneider, Christina Rautenberg, Hans Christian Reinhardt, Linette Bosques, Michael Heuser, Victoria Panagiota iD und 18 weitere

American Journal of Hematology · 2024-05 · 99 (5) · 844-853

DOI: 10.1002/ajh.27252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 15.02.2024. Verfasst von Nico Gagelmann und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Hematopoietic Stem Cell Transplantation, Thrombocytopenia, Graft vs Host Disease. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Splenomegaly is the clinical hallmark of myelofibrosis. Splenomegaly at the time of allogeneic hematopoietic cell transplantation (HCT) is associated with graft failure and poor graft function. Strategies to reduce spleen size before HCT especially after failure to Janus kinase (JAK) inhibition represent unmet clinical needs in the field. Here, we leveraged a global collaboration to investigate the safety and efficacy of splenic irradiation as part of the HCT platform for patients with myelofibrosis. We included 59 patients, receiving irradiation within a median of 2 weeks (range, 0.9–12 weeks) before HCT. Overall, the median spleen size prior to irradiation was 23 cm (range, 14–35). Splenic irradiation resulted in a significant and rapid spleen size reduction in 97% of patients (57/59), with a median decrease of 5.0 cm (95% confidence interval, 4.1–6.3 cm). The most frequent adverse event was thrombocytopenia, with no correlation between irradiation dose and hematological toxicities. The 3‐year overall survival was 62% (95% CI, 48%–76%) and 1‐year non‐relapse mortality was 26% (95% CI, 14%–38%). Independent predictors for survival were severe thrombocytopenia and anemia before irradiation, transplant‐specific risk score, higher‐intensity conditioning, and present portal vein thrombosis. When using a propensity score matching adjusted for common confounders, splenic irradiation was associated with significantly reduced relapse ( p = .01), showing a 3‐year incidence of 12% for splenic irradiation versus 29% for patients with immediate HCT and 38% for patients receiving splenectomy. In conclusion, splenic irradiation immediately before HCT is a reasonable approach in patients experiencing JAK inhibition failure and is associated with a low incidence of relapse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisHematopoietic Stem Cell TransplantationThrombocytopeniaGraft vs Host DiseaseHumansSpleenSplenomegalyRecurrenceTransplantation Conditioning

Autor:innen und Institutionen

  • Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Hospital, University Vita-Salute San Raffaele, Milan, Italy.
  • Department of Hematology and Bone Marrow Transplantation, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
  • Department of Hematology, University Medical Center Ljubljana, Ljubljana, Slovenia.
  • Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital of Essen, Germany.

ORCID-Profile: Nico Gagelmann, Victoria Panagiota, Carmelo Gurnari, Marie Robin, Nelson Hamerschlak, Raffaella Greco

Zitieren

APA

Gagelmann, N., Hobbs, G. S., Campodonico, E., Helbig, G., Novak, P., Schroeder, T., Schneider, A., Rautenberg, C., Reinhardt, H. C., Bosques, L., Heuser, M., Panagiota, V., Thol, F., Gurnari, C., Maciejewski, J. P., Ciceri, F., Rathje, K., Robin, M., Pagliuca, S., …, & Kröger, N. (2024). Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis. American Journal of Hematology, 99(5), 844-853. https://doi.org/10.1002/ajh.27252

Vancouver

Gagelmann N, Hobbs GS, Campodonico E, Helbig G, Novak P, Schroeder T, et al. Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis. American Journal of Hematology. 2024;99(5):844-853. doi:10.1002/ajh.27252

BibTeX
@article{Gagelmann2024,
  author = {Gagelmann, Nico and Hobbs, Gabriela S and Campodonico, Edoardo and Helbig, Grzegorz and Novak, Polona and Schroeder, Thomas and Schneider, Artur and Rautenberg, Christina and Reinhardt, Hans Christian and Bosques, Linette and Heuser, Michael and Panagiota, Victoria and Thol, Felicitas and Gurnari, Carmelo and Maciejewski, Jaroslaw P and Ciceri, Fabio and Rathje, Kristin and Robin, Marie and Pagliuca, Simona and Rubio, Marie-Thérèse and Rocha, Vanderson and Funke, Vaneuza and Hamerschlak, Nelson and Salit, Rachel and Scott, Bart L and Duarte, Fernando and Mitrus, Iwona and Czerw, Tomasz and Greco, Raffaella and Kröger, Nicolaus},
  title = {Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis},
  journal = {American Journal of Hematology},
  year = {2024},
  volume = {99},
  number = {5},
  pages = {844--853},
  doi = {10.1002/ajh.27252}
}
Kostenlos starten →